Close menu




biotechnology

Photo credits: pixabay.com

Commented by Fabian Lorenz on November 20th, 2026 | 05:55 CET

Shock at Deutz! Opportunity at Evotec? Buy recommendation for Desert Gold!

  • gold
  • precious metals
  • defence
  • biotechnology

Created and Published on Behalf of Desert Gold Ventures Inc.

Shock at Deutz! After the share price plunged from over EUR 13, a short-seller attack is adding to the uncertainty. Serious allegations surrounding the multibillion-euro takeover of FFG are putting the former stock market darling under pressure. Investors also seem to have no confidence in Evotec. Even positive news from the collaboration with Bristol Myers Squibb cannot help the shares get back on their feet. Does the multi-year low offer a buying opportunity? By contrast, an exciting phase lies ahead for Desert Gold Ventures. The explorer is preparing for gold production, and analysts see potential for the share price to multiply. Although the gold sector as a whole is reeling after the price slump below USD 3,800, precious metals expert Markus Bußler remains invested and is betting on a rebound.

Read

Commented by Fabian Lorenz on October 23rd, 2026 | 05:38 CEST

Strong News and Buy Recommendations: Vonovia, Evotec and Lahontan Gold

  • precious metals
  • gold
  • silver
  • biotechnology
  • real estate

Strong news from Lahontan Gold. The explorer has published a positive preliminary economic assessment (PEA) for its Santa Fe gold-silver project in Nevada. The after-tax net present value stands at approximately USD 820 million, significantly exceeding the company's current market capitalisation. The company is also working to expand the resource base. While Lahontan Gold shareholders can look forward to the approaching start of gold production, Vonovia shareholders face an uncertain future. The expropriation scenario is weighing on sentiment. Even JPMorgan's assessment that these concerns are exaggerated does little to change the picture. In a worst-case scenario, the German government would intervene. And what about Evotec? The shares have gained more than 10% in recent trading days. The appointment of a new executive at Novo Nordisk could inject fresh momentum into the company.

Read